GRFS
Grifols, S.A.
NASDAQ · Healthcare · Drug Manufacturers - General · ES
$7.80
−1.02%Aug 13, 2026, 20:45 UTC
Grifols temporarily paused plasma collection at all its donation centres across Canada.
Aug 10, 2026, 11:00 UTC
Grifols announced the completion of the clinical portion of its Phase 3 SPARTA study evaluating Prolastin-C in patients with emphysema due to alpha-1 antitrypsin deficiency.
Source:Jul 16, 2026, 12:00 UTC
Grifols dosed first patients in two Phase 3 trials to expand indications for its immunoglobulins GAMUNEX-C and XEMBIFY.
Source:Jul 15, 2026, 23:59 UTC
Health Canada flagged concerns in an inspection of Grifols' head office, including inappropriate clearance of donors with Creutzfeldt-Jakob Disease risk factors.
Jul 3, 2026, 11:45 UTC
Grifols reorganizes its operating model into a dual structure, separating its US plasma division from the rest of the world, with executive changes including the departure of Roland Wandeler.
Source:Jul 3, 2026, 11:45 UTC
Roland Wandeler will leave Grifols on 30 September to pursue new professional projects.
Source:Jun 15, 2026, 12:00 UTC
Grifols launched FESILTY (fibrinogen, human-chmt) in the U.S. for treating congenital fibrinogen deficiency.
Source: